Is Egrifta (Tesamorelin) Legal in Maryland? What Women Need to Know

The short answer on legality in Maryland

Egrifta (tesamorelin) is legal in Maryland. Full stop. It is an FDA-approved prescription medicine, not a controlled substance, and Maryland imposes no additional state-level restrictions beyond the standard prescription-only requirement. Any licensed Maryland prescriber, including physicians, nurse practitioners, and physician assistants operating within their scope, can write a prescription for it. Any pharmacy licensed to do business in Maryland, whether brick-and-mortar or mail-order, can fill it.

The confusion about legality usually traces back to two things: the broader "peptide gray area" conversation online, and the separate question of compounded tesamorelin. This article addresses both, with specific attention to how the legal and clinical picture looks for women across different life stages.

Why peptides in general feel legally murky

Many growth-hormone-releasing peptides, such as CJC-1295, ipamorelin, and GHRP-6, exist in a genuine regulatory gray zone. The FDA placed them on its bulks list of prohibited compounding substances, which means licensed compounding pharmacies cannot legally use them as starting ingredients. Tesamorelin is different. It has a full FDA approval (NDA 022505) as Egrifta, which gives it a clearly defined legal pathway.

The brand vs. Compounded distinction matters

Egrifta and Egrifta SV (the reformulated version) are the brand-name, FDA-approved products manufactured by Theratechnologies. They are the only tesamorelin products that have gone through the full FDA approval process.

Compounded tesamorelin occupies a narrower but still legal space. A 503A pharmacy (a traditional compounding pharmacy) may prepare tesamorelin for an individual patient with a valid prescription, provided the compounded preparation does not copy a commercially available product in a way that violates FDA guidance. A 503B outsourcing facility may produce it in larger quantities under current good manufacturing practice standards. Neither category can use tesamorelin sourced from unregulated raw-material suppliers or sold as a "research chemical."

If someone is selling you tesamorelin as a research chemical, or shipping it without a prescription, that product is not legal for human use regardless of what state you live in.

How federal law governs tesamorelin and why Maryland follows it

The United States has a unified federal framework for prescription drugs. Once the FDA approves a drug and it is not scheduled under the Controlled Substances Act, it flows through a standard prescription model across all 50 states. Maryland does not have a competing state drug-approval system.

The Controlled Substances Act does not cover tesamorelin

Tesamorelin is not listed in any schedule of the Controlled Substances Act. This means:

• There is no DEA registration required to prescribe it.
• There are no quantity limits tied to controlled-substance schedules.
• Possessing it with a valid prescription carries no special legal risk.

Some growth hormone peptide secretagogues have been placed under Schedule III (anabolic steroids are there; certain GH secretagogues have faced scrutiny in sporting contexts), but tesamorelin has not been scheduled.

Maryland Board of Pharmacy and prescriber licensing

The Maryland Board of Pharmacy regulates who can dispense prescription drugs in the state. Tesamorelin prescribed in Maryland must be dispensed by a pharmacy that holds a current Maryland permit. Out-of-state mail-order pharmacies serving Maryland patients must be registered with the Board.

Maryland prescribers operate under the Maryland Medical Practice Act, which allows them to prescribe FDA-approved drugs for off-label indications when there is a reasonable clinical basis. This matters for women, because the only FDA-approved indication for tesamorelin is HIV-associated lipodystrophy, and most women seeking it are interested in off-label applications related to visceral fat, metabolic health, or body composition.

Off-label prescribing of FDA-approved drugs is legal. It is also common: roughly one in five prescriptions written in the United States is for an off-label use.

What tesamorelin actually does and why women are asking about it

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary and stimulates pulsatile growth hormone secretion, which in turn raises insulin-like growth factor 1 (IGF-1). The downstream effect that got it FDA approval is a meaningful reduction in visceral adipose tissue (VAT), the metabolically active fat that sits around abdominal organs.

The phase 3 LIPO trials in HIV-positive patients demonstrated a reduction in VAT of approximately 15 to 20 percent at 26 weeks with 2 mg subcutaneous daily dosing, compared with placebo. Those trials enrolled both men and women, though women were a minority of participants, a pattern that plagues the peptide literature broadly.

Women are asking about tesamorelin for several reasons that go beyond HIV lipodystrophy:

• Perimenopause and menopause. Estrogen decline accelerates visceral fat accumulation. Some clinicians use tesamorelin off-label in this context, though direct trial data in postmenopausal women is thin.
• PCOS. Hyperandrogenism and insulin resistance in PCOS are associated with increased VAT, and growth hormone axis dysregulation has been documented in some PCOS phenotypes. Research here is early-stage.
• General body composition and metabolic health. GH secretion naturally declines with age in both sexes, but the timing overlaps significantly with perimenopause in women, making it a point of clinical interest.
• Cognitive function. A small secondary analysis from the HIV lipodystrophy trials found a signal for improved cognitive performance with tesamorelin, a finding that attracted attention given the cognitive changes many women report in perimenopause.

A practical way to think about tesamorelin's role across female life stages:

| Life Stage | Potential Clinical Interest | Evidence Quality | |---|---|---| | Reproductive years (PCOS) | VAT reduction, GH axis | Preliminary, extrapolated | | Perimenopause | VAT increase with estrogen decline | Off-label; no RCT in this group | | Postmenopause | Metabolic risk, body composition | Extrapolated from HIV trials | | HIV-associated lipodystrophy (any age) | FDA-approved indication | Phase 3 RCT data |

This framework is original to WomanRx; it does not appear in published guidelines because no guideline currently addresses tesamorelin in non-HIV female populations.

Sex-specific physiology: how being a woman changes the tesamorelin picture

This section is where most online articles fall short. The LIPO trials enrolled predominantly men. What is known about tesamorelin in women comes from subgroup data and extrapolation.

IGF-1 levels run differently across the menstrual cycle and with menopause

IGF-1 is the primary biomarker used to monitor tesamorelin therapy and avoid excess GH stimulation. In premenopausal women, IGF-1 has modest cycle-related variation. More clinically relevant: estrogen status significantly affects IGF-1. Oral estrogen lowers IGF-1 by inducing hepatic GH resistance, meaning a woman on oral hormone therapy may have a blunted or different IGF-1 response to tesamorelin compared with a woman not on oral estrogen. Transdermal estrogen does not carry the same hepatic first-pass effect and has a more modest impact on IGF-1.

If you are on menopausal hormone therapy, your prescriber needs to know the route of administration (oral vs. Transdermal) before interpreting your IGF-1 results.

Dose considerations in women

The FDA-approved dose is 2 mg subcutaneously once daily. No weight-based dosing adjustment is specified in the label. The LIPO trials used this flat dose in participants across a range of body sizes and both sexes.

Some clinicians use lower doses (0.5 to 1 mg) in off-label female patients to reduce the risk of fluid retention and IGF-1 overshoot, but this is clinical practice, not a studied protocol. Women generally have lower lean mass and different GH secretory patterns than men, which is a reasonable physiological rationale for cautious dose titration starting low.

Side effects that may be more prominent in women

The most common adverse effects in the LIPO trials were injection-site reactions, fluid retention, arthralgias, and peripheral edema. Fluid retention deserves specific mention for women because:

• Women with premenstrual fluid shifts may find symptoms amplified.
• Women with a history of estrogen-related fluid retention (e.g., from combined oral contraceptives) may be more sensitive.
• Carpal tunnel syndrome, a known GH excess effect, is already more common in women and in pregnancy.

Pregnancy, lactation, and contraception: required reading before you start

Tesamorelin is contraindicated in pregnancy. The FDA label carries a contraindication for use in pregnant women based on animal reproductive toxicology data showing fetal harm, and the absence of adequate human data makes this a hard stop.

Under the FDA's current Pregnancy and Lactation Labeling Rule (PLLR), tesamorelin's prescribing information states it should not be used during pregnancy. In older classification terms this maps to the equivalent of a Category X or at minimum a strong Category D, meaning the risk clearly outweighs any hypothetical benefit.

Practical implications by life stage:

• Trying to conceive. Discontinue tesamorelin before attempting conception. Given its mechanism, there is no established safe window for continued use while trying to become pregnant.
• Reproductive years on tesamorelin. Reliable contraception is expected while on therapy. Discuss contraceptive options with your prescriber. Tesamorelin does not appear to interact with hormonal contraceptive metabolism, but this has not been formally studied.
• Postpartum and lactation. There are no human lactation studies. Tesamorelin's molecular weight suggests it may be present in breast milk, but oral bioavailability of peptides is low, so infant exposure from breastfeeding is likely to be minimal, though "likely minimal" is not the same as "proven safe." LactMed does not currently list tesamorelin, reflecting the absence of published data rather than confirmed safety. Avoid use while breastfeeding until data exist.
• Perimenopause/postmenopause. Pregnancy is not a concern once menopause is confirmed (12 months of amenorrhea), but women in perimenopause retain fertility and should use contraception.

Who this is right for and who should wait

Good candidates, framed by life stage

• Postmenopausal women with documented HIV-associated lipodystrophy (FDA-approved indication).
• Perimenopausal women with progressive visceral fat accumulation, metabolic syndrome features, and a prescriber experienced in off-label peptide use who will monitor IGF-1 closely.
• Women with confirmed growth hormone deficiency (separate from HIV; a different but related off-label scenario) who have not responded to or cannot access other treatments.

Women who should not use tesamorelin

• Pregnant women or those actively trying to conceive.
• Women breastfeeding (no safety data).
• Women with active malignancy: GH stimulation is contraindicated in cancer. The Endocrine Society guidelines on GH in adults explicitly list active malignancy as a contraindication to GH-axis stimulation.
• Women with diabetic retinopathy: IGF-1 elevation can worsen retinopathy.
• Women with pituitary tumors or structural pituitary disease: GHRH analogs stimulate a pituitary axis that may be compromised.
• Women with poorly controlled diabetes: tesamorelin raises blood glucose through GH-induced insulin resistance. In the LIPO trials, fasting glucose increased by a mean of 4.4 mg/dL vs. Placebo at 26 weeks.

How to get Egrifta (tesamorelin) in Maryland: step by step

Getting a legal tesamorelin prescription in Maryland follows the same pathway as any other prescription medication.

Step 1: Find a licensed Maryland prescriber

Telehealth has made this more accessible. A Maryland-licensed physician, nurse practitioner (under Maryland NP prescriptive authority rules), or PA can prescribe tesamorelin. Look for providers with training in endocrinology, obesity medicine, women's health, or functional/integrative medicine who explicitly mention GH peptides in their scope of practice.

WomanRx clinicians are licensed in Maryland and can evaluate whether tesamorelin fits your clinical picture.

Step 2: Expect baseline labs

A responsible prescriber will check IGF-1, fasting glucose, HbA1c, a comprehensive metabolic panel, and, for women in reproductive years, a pregnancy test before prescribing.

Step 3: Pharmacy dispensing

Brand-name Egrifta or Egrifta SV is dispensed through specialty pharmacies and some retail chains. Compounded tesamorelin from a licensed 503A or 503B pharmacy is another route and may be less expensive, though insurance rarely covers compounded versions. Confirm the pharmacy holds a current Maryland permit or is registered as an out-of-state pharmacy with the Maryland Board of Pharmacy if dispensing by mail.

Step 4: Ongoing monitoring

Monthly IGF-1 checks for the first three months, then quarterly, are a reasonable monitoring schedule based on the LIPO trial protocol and Endocrine Society GH deficiency guidelines. Your prescriber should also track fasting glucose and watch for signs of fluid retention or carpal tunnel symptoms.

The evidence gap for women: what we know and what we do not

Women were underrepresented in the key LIPO trials. The most-cited publication, Stanley et al. (2012) in JAMA, enrolled participants who were approximately 85 percent male. This is not unusual in peptide and GH research, but it means:

• The 15 to 20 percent VAT reduction figure cannot be confidently applied to women without reservation.
• Side-effect rates, particularly fluid retention and glucose effects, may differ by sex and hormonal status in ways the trials were not powered to detect.
• Optimal dosing in postmenopausal women on hormone therapy has not been established.

The Endocrine Society has noted that sex and estrogen status should be considered when interpreting IGF-1 targets for GH-axis therapies, but specific tesamorelin guidelines for women do not yet exist. If a clinician tells you the evidence base for women is as strong as for men, they are overstating it.

PCOS and tesamorelin: an early-stage conversation

PCOS affects 8 to 13 percent of reproductive-age women and is characterized in part by visceral fat accumulation, insulin resistance, and, in some phenotypes, growth hormone axis dysregulation. A small number of researchers have examined GHRH analogs and growth hormone secretagogues in PCOS, but no published randomized trial has tested tesamorelin specifically in women with PCOS.

What exists: case series and mechanistic work showing that GH pulsatility is blunted in some PCOS phenotypes, and that improving GH axis signaling may improve insulin sensitivity. This is a rationale for investigation, not a basis for routine clinical use. If a clinician is offering you tesamorelin specifically as a PCOS treatment, ask them to show you the evidence. It is thin.

Perimenopause, menopause, and visceral fat: the biological case for interest

Estrogen has a direct effect on fat distribution. Before menopause, most women store fat preferentially in the gluteofemoral region. After menopause, fat redistributes toward the abdomen and viscera. Epidemiological data show a 49 percent increase in visceral fat during the menopausal transition independent of total body weight change.

Growth hormone secretion also declines with age, and the timing overlaps with perimenopause. Whether tesamorelin can partially offset menopausal visceral fat gain is a reasonable question. The answer is: probably, based on mechanism and HIV trial data, but no perimenopause-specific trial has been done. The Menopause Society (NAMS) 2023 position statement does not address tesamorelin, reflecting the absence of trial data in this population.